Evaluation of Intralipid efficacy for decreasing Amphotericin B-related nephrotoxicity

Evaluation of Intralipid efficacy for decreasing Amphotericin B-related nephrotoxicity in patients with fungal infections admitted in Amir-Alam and Imam Khomeini hospitals in Tehran during 1390-1391

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2012110411364N1

Enrollment

Registered

2012-12-01

Start date

2012-03-15

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Fungal Infections. Condition 2: Fungal Infections. Condition 3: Fungal Infections. Aspergillosis Zygomycosis Unspecified mycosis

Interventions

Intervention 1: In intervention group, 1 milligram per kilogram of Amphotericin B is mixed with dextrose 5% in a concentration of 0.1 milligram per milliliter and infused over a 4-hour period dail

Treatment - Other

In intervention group, 1 milligram per kilogram of Amphotericin B is mixed with dextrose 5% in a concentration of 0.1 milligram per milliliter and infused over a 4-hour period daily.Treatment days

In control group, 1 milligram per kilogram of Amphotericin B is mixed with dextrose 5% in a concentration of 0.1 milligram per milliliter and infused over a 4-hour period daily. Treatment days with Am

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients with fungal infections admitted in Amir-Alam and Imam Khomeini hospitals in Tehran during 1390-1391 who need Amphotericin B for treatment. Exclusion criteria: pathologic hyperlipidemia; patient receiving other nephrotoxic drugs like aminoglycoside simultaneously; severe liver failure or cirrhosis; ESRD under hemodialysis or peritoneal dialysis; baseline serum creatinine over 2mg/dL; hypersensitivity to fat emulsions,egg and soya; pancreatitis

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Serum creatinie level. Timepoint: baseline and daily during intervention. Method of measurement: milligram per deciliter (mg/dL) with blood sampling.	—

Secondary

Measure	Time frame
Serum potassium level. Timepoint: baseline and daily during intervention. Method of measurement: milliequivalent per liter (mEq/L) with blood sampling.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyed Ali Dehghan Manshadi M.D.

Tehran University of Medical Sciences

a_dehghnm@razi.tums.ac.ir+98 21 6658 1598

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026